CRITERIA PERSISTANCE SEVERITY
  RR IC 95% RR IC 95%
Duration of symptoms        
≥ 6 weeks< 6  months 0.84 (0.67-1.06) 0.93 (0.37 – 2.27)
≥ 6 months 1.19 (0.94-1.52) 1.08 (0.44 – 2.68)
Painful bilateral compression of  MTPs 0.96 (0.64 -1.44) 0.59 (0.30-1.15)
Basal symmetry 1.42 (0.68-2.93) 1.95 (1.41-2.68)*
Basal rheumatoidnodules 1.24 (1.07-1.43)* 2.31 (1.60 – 3,40)*
Radiologicalerosions in hands and feet 0.99 (0.76-1.62) 2.67 (1.17-6,09)*
RF ≥ 1/80 1.44 (1.05-1.97)* 1.29 (0.57-2.92)
Anti-CCP > 5 mg 1.08 (0.72-1.62) 0.89 (0.44 – 1.81)
CTX-II > 0.3 ng/ml
RF (+)  plus Anti-CCP (+) plus CTx-II (+)
RF (+) plus Anti-CCP (+) plus  CTx-II (-)
RF (+) plus Anti CCP(-) plus  CTx-II (+)
RF (-) plus Anti CCP (+) plus  CTx-II (+)
DAS 28 > 4,19 		1.36
2.72
2.31
2.45
2.15
2.67		 (0.93-1.99)
(1.71-3.61)* (1.60-3.40)* (1.65-3.42)* (0.71-.1.61)* (1.75-3.78)*		 1.36
3.88
3.65
3.77
2.65
3.11		 (0.68 – 2.73) (2.11-5.08)* (2.08-4.58)* (2.10-5.03)* (1.19-5.09)* (2.89-4.11)*
*p ≤ 0,05 MTPs: Metatarsophalangeal; RF: Rheumatoid Factor; Anti-CCP: Antibodies against citrullinated peptides; TX-II: C-telopeptide
Table 4: Persistence of the activity and severity by radiological damage at 12 months follow-up.